Biocryst Pharmaceuticals Inc financial data

Symbol
BCRX on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
4505 Emperor Boulevard, Suite 200, Durham, NC
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-K - Q4 2024 - Feb 25, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 295 % -38.2%
Quick Ratio 13 % -51.8%
Return On Equity 18.8 % -67.2%
Return On Assets -18.5 % +57.6%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 209M shares +1.25%
Common Stock, Shares, Outstanding 209M shares +1.35%
Entity Public Float 1.26B USD -4.4%
Common Stock, Value, Issued 2.09M USD +1.31%
Weighted Average Number of Shares Outstanding, Basic 207M shares +7.54%
Weighted Average Number of Shares Outstanding, Diluted 207M shares +7.54%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 175M USD -19.4%
Costs and Expenses 453M USD +4.17%
Operating Income (Loss) -2.54M USD +97.5%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -87M USD +61.6%
Income Tax Expense (Benefit) 1.93M USD +522%
Net Income (Loss) Attributable to Parent -88.9M USD +60.8%
Earnings Per Share, Basic -0.43 USD/shares +63.6%
Earnings Per Share, Diluted -0.43 USD/shares +63.6%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 105M USD -5.36%
Accounts Receivable, after Allowance for Credit Loss, Current 79.1M USD +38.8%
Inventory, Net 31.3M USD +9.03%
Assets, Current 422M USD -14.9%
Property, Plant and Equipment, Net 7.78M USD -1.68%
Operating Lease, Right-of-Use Asset 8.06M USD -7.15%
Other Assets, Noncurrent 5.16M USD +6346%
Assets 490M USD -5.13%
Accounts Payable, Current 11.6M USD -44.3%
Employee-related Liabilities, Current 48.6M USD +33.2%
Accrued Liabilities, Current 113M USD +10.1%
Liabilities, Current 160M USD +6.93%
Operating Lease, Liability, Noncurrent 7.92M USD -5.55%
Liabilities 966M USD -0.63%
Accumulated Other Comprehensive Income (Loss), Net of Tax 921K USD -31.1%
Retained Earnings (Accumulated Deficit) -1.77B USD -5.29%
Stockholders' Equity Attributable to Parent -476M USD -4.48%
Liabilities and Equity 490M USD -5.13%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -53.7M USD -13%
Net Cash Provided by (Used in) Financing Activities -1.05M USD -121%
Net Cash Provided by (Used in) Investing Activities 28.8M USD
Common Stock, Shares Authorized 450M shares 0%
Common Stock, Shares, Issued 209M shares +1.35%
Common Stock, Par or Stated Value Per Share 0.01 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -26.3M USD +82.4%
Interest Paid, Excluding Capitalized Interest, Operating Activities 4.99M USD -30.2%
Deferred Tax Assets, Valuation Allowance 449M USD +2.66%
Deferred Tax Assets, Gross 453M USD +2.69%
Operating Lease, Liability 8.86M USD -6.21%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -89.3M USD +60.4%
Lessee, Operating Lease, Liability, to be Paid 14.6M USD -8.78%
Property, Plant and Equipment, Gross 20.1M USD +5.26%
Operating Lease, Liability, Current 937K USD -11.4%
Lessee, Operating Lease, Liability, to be Paid, Year Two 1.74M USD +2.41%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.86M USD -7.8%
Operating Lease, Weighted Average Discount Rate, Percent 0.11 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 5.69M USD -12.5%
Lessee, Operating Lease, Liability, to be Paid, Year Three 1.65M USD +9.34%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5M shares 0%
Unrecognized Tax Benefits 14.7M USD +2.46%
Lessee, Operating Lease, Liability, to be Paid, Year Four 1.38M USD -5.47%
Operating Lease, Payments 2.02M USD +44%
Additional Paid in Capital 1.29B USD +5.63%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 306K USD -24.4%
Share-based Payment Arrangement, Expense 65.4M USD +17.6%
Interest Expense 101M USD -5.93%
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares 0%